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Summary The expression of the c-erbB-1, c-myc, Ha/N-ras and c-fos oncogenes was investigated in 62
astrocytomas of low, intermediate and high grades by immunogold silver histochemistry. Elevated expression
of c-erbB-l was observed in 95%, 48% and 86% of low, intermediate and high grade tumours respectively,
c-myc in 5%, 33% and 76% respectively, Ha/N-ras in 0, 43% and 71% respectively and c-fos in 55%, 48%
and 52% respectively. Controls included normal brain and tumour sections immunoreacted with pre-immune
serum or with antisera absorbed with synthetic peptides. Analysis of co-overexpression revealed that low grade
tumours co-overexpressed a maximum of two of these genes, intermediate grade tumours a maximum of three
of these genes, while co-overexpression of all four genes was observed in some high grade tumours.
Co-overexpression of c-erbB-1 and c-fos was frequently observed in low grade astrocytomas and may be
predictive of non-progression. On the other hand, there was a statistically significant increase in the number of
tumours overexpressing Ha/N-ras or c-myc with increasing grade of tumour, suggesting that overexpression of
these two oncogenes may be indicative of progression.
Gliomas are tumours of non-neuronal, supporting cells of the
brain. They may be of astrocytic, oligodendroglial or epen-
dymal lineage and mixed gliomas may also occur (Zulch,
1986). Astrocytomas are the commonest of the glial tumours
and comprise over 45% of childhood (Becker & Yates, 1986)
and 50% of adult primary brain tumours (Zulch, 1986).
There is considerable variation in the behaviour of astro-
cytomas. Some remain as indolent low grade tumours while
others are believed to progress to higher grades of malig-
nancy. Determination of the likelihood of progression pre-
sently relies heavily on histological criteria. Appraisal of the
potential for progression would be greatly enhanced by the
availability of biological markers, especially if these could be
quantitated.
Oncogenes have been shown to act as useful markers of
progression in some human tumours. Studies of over 800
patients with neuroblastoma (Bertram & Berthold, 1987;
Nakagarawa et al., 1987; Tsuda et al., 1987, and see Brodeur,
1990 for review), a tumour of primitive neuronal cells which
occurs predominantly outside the brain, have shown that
amplification of the N-myc oncogene is associated with rapid
progression and poor prognosis. Another oncogene which
may serve as a marker of prognosis is c-erbB-2 (or HER-2 or
neu). Initial studies correlated c-erbB-2 amplification in
breast carcinoma with poorer prognosis (Slamon et al.,
1987). However these findings have been disputed due to the
considerable variation in other clinical parameters (for review
see Maguire & Green, 1989). Recent data, however, indicate
that c-erbB-2 amplification may be an indicator of behaviour
of the comedo subtype of breast carcinoma (Van de Vijver et
al., 1988; Borg et al., 1989).
Activation of a number of oncogenes has been reported in
astrocytomas but to date, none of these has been shown to
be associated with progression. The best characterised is the
c-erbB-1 oncogene which encodes the epidermal growth fac-
tor receptor (EGF-R) (Dalla-Favera & Cesarman, 1986).
Amplification ofc-erbB-1 has been reported to occur in up to
40% of high grade gliomas. This may involve the entire gene
or selectively, those regions encoding the extracellular, cyto-
plasmic or intracellular domains of the receptor protein
(Liberman et al., 1985; Malden et al., 1988; Wong et al.,
1987). Elevated levels of c-erbB-l mRNA occurred indepen-
dently of amplification in 17 of 19 (89%) gliomas in one
study (Malden et al., 1988). Activation, characterised by
elevated mRNA levels, of c-myc (Englehard et al., 1989;
Trent et al., 1986), N-myc (Garson et al., 1985; Kinzler et al.,
1986; Fujimoto et al., 1989), N-ras (Gerosa et al., 1988) and
gli (Kinzler et al., 1987) has also been reported in glial
tumours.
The above data were derived from primary tumours.
Studies of astrocytoma-derived cell lines have demonstrated a
different profile of oncogene activation e.g. c-abl, c-sis, c-ros
and c-raf (Blin et al., 1987; Henn et al., 1986; Fukui et al.,
1987; Wu & Chikaraishi, 1990). These studies suggest that
examination of biopsy-derived material from primary astro-
cytic tumours is more appropriate than cell lines to inves-
tigate the in vivo activation of oncogenes.
In this study we have investigated the overexpression of
four oncogenes in 62 astrocytic tumours of differing grades
to determine whether there is an association between the
profile of expression and tumour grade. It is not possible to
study the same tumour in vivo at different time points and we
believe this to be the most appropriate method of determin-
ing an association between oncogene activity and progres-
sion. The oncogenes investigated were c-erbB-l the product
of which (EGF-R) is a membrane associated tyrosine kinase
receptor, c-myc and c-fos the products of which are pos-
tulated to have DNA binding activity, and ras which encodes
a G-binding protein active on the inner side of the cytoplas-
mic membrane (Dalla-Favera & Cesarman, 1986). An associ-
ation between activation of c-erbB-1 and c-myc and N-ras in
astrocytomas has been established, while that ofc-fos has not
previously been reported. These oncogenes were selected in
this study to determine if a pattern of co-activation of cell-
membrane-associated, cytoplasmic and nuclear oncogenes
could be observed in different tumour grades. Our data show
that overexpression of c-erbB-1, or c-fos is probably not
useful in predicting biological behaviour, while that of c-myc
or Ha/N-ras may be. In addition it is also shown that
co-overexpression of up to four oncogenes is most common
in high grade astrocytomas.
Materials and methods
Materials
Monoclonal antibodies against the products of the c-erbB-l
and c-myc oncogenes and polyclonal antisera (raised in
sheep) against the c-fos and ras oncogene products were
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purchased from Cambridge Research Biochemicals (Gad-
brook Park, Norwich UK). The antibody against the c-erbB-
1 gene product was raised against a 12-residue peptide
derived from the extracellular domain of the EGF-R protein
sequence, that against the c-myc gene product was raised
against a 31-residue peptide from human c-myc and that
against the c-fos gene product was raised against an 11-
residue peptide from human c-fos. The ras antiserum was
raised against an N-terminal 18-residue peptide common to
all proteins. However this antibody was tested using cell lines
overexpressing N-ras or Ha-ras only. Since the ability of the
antibody to detect Ki-ras is unproven, we have not assumed
that Ki-ras was also present and tumours showing positive
immunoreactivity are described as positive for Ha/N-ras.
Also none of the above antisera distinguish between wild-
type and mutated gene products. The specificity of each of
these antibody preparations has been demonstrated (Yeaton
et al., 1983; Lacal & Tronick, 1988; Evan & Hancock, 1985).
Secondary antisera (gold-conjugated goat-anti-mouse and
goat-anti-rabbit IgG) were purchased from Sigma (St. Louis
Mo. USA) and a linking antiserum (rabbit-anti-sheep IgG)
from Dakopatts (Glostrup, Denmark). Synthetic peptides for
EGF-R, c-myc, HaIN-ras and c-fos were obtained from Cam-
bridge Research Biochemicals. Silver nitrate and hydro-
quinone (1,4 benzenediol) were purchased from Sigma.
Tissue
Sixty-two astrocytomas comprising 20 low grade (juvenile
pilocytic astrocytomas) (Zulch, 1986), 21 intermediate grade
tumours (anaplastic astrocytomas) and 21 high grade
tumours (glioblastoma multiforme) (Ringertz, 1950), and
eight cases of normal brain and/or brain adjacent to tumour
were used in this study. Cases of high and intermediate grade
tumours and normal brain and brain adjacent to tumour
were selected sequentially from archival material in the
Department of Anatomical Pathology, Royal Melbourne
Hospital and low grade tumours from archival material in
the Department of Anatomical Pathology, Royal Children's
Hospital, Melbourne. All samples had been initially derived
from surgical biopsies or resections. Samples from both hos-
pitals were fixed in 10% formalin and processed in an iden-
tical manner. The original Haematoxylin and Eosin (H&E)-
stained paraffin sections were reviewed and tumours graded
according to the Ringertz criteria (Ringertz, 1950).
Immunogold silver staining (IGSS)
The techique used was adapted from Holgate et al. (1983).
Briefly 6 JL sections were dewaxed in xylene, rehydrated in
graded alcohols, immersed in Lugol's Iodine for 5 min and
decolourised in 2.5% sodium thiosulphate. After equilibra-
tion in Tris-buffered saline, pH 7.4 (TBS) sections were
blocked with 10% normal swine serum or newborn calf
serum in TBS for 15 min at room temperature in a moist
chamber. Sections were then incubated with the primary
antibody at the appropriate dilution in TBS containing 10%
serum for 1 to 2 h at room temperature or 4 to 16 h at 4°C.
For monoclonal antibodies, sections were washed briefly in
TBS and incubated with a goat-anti-mouse IgG/gold con-
jugate at a dilution of 1 in 50 in TBS containing 10% serum
for 1 to 2 h at room temperature or 4 to 16 h at 4°C.
Sections were then sequentially washed in TBS and distilled
water and incubated for 3 min in physical development solu-
tion in the dark. Sections were then fixed in 5% sodium
thiosulphate for 3 min and rinsed in distilled water. They
were then counterstained in Nuclear Fast Red B, dehydrated
in graded alcohols, cleared in xylene, mounted and examined
by light microscopy.
Sections immunoreacted with polyclonal antisera were
rinsed briefly in TBS following incubation with the primary
antiserum and then incubated with a rabbit-anti-sheep IgG
linking antiserum for 1 h at room temperature. Sections were
then incubated with a goat-anti-rabbit IgG/gold conjugate
and processed exactly as described for monoclonal
antibodies.
Negative controls included (a) sections immunoreacted in
the absence of primary antibody and (b) sections
immunoreacted with antibody preparations which had been
absorbed with the oncoprotein synthetic peptides as follows.
Each of the synthetic peptides was conjugated to Sepharose
beads (Harlow & Lane, 1988) and each preparation of con-
jugated peptide was then incubated with the corresponding
antibody preparation for 1 h at room temperature. The beads
were then removed by centrifugation and the supernatant
collected. The supernatant was then used as described above
for the primary antibody.
Immunoreactivity was assessed by light microscopy as a
greater density of silver grains over nuclei or over the cytop-
lasmic compartment of cells in tumour sections (Figure 1)
compared with negative controls. In both types of negative
controls, the grain density averaged 10 per x 1000 field.
Immunoreactivity was regarded as positive if the grain den-
sity was 10 or more per individual cell. Although the IGSS
technique can be used to semi-quantify oncoprotein levels by
grain counting, we did not attempt quantitation in this study
and only assessed whether overexpression of each oncogene
was occurring in each tumour. The product of any one
oncogene was regarded as being overexpressed if
immunoreactivity could be detected in tumour sections at
dilutions higher than in sections of normal white matter. To
determine these dilutions, sections from eight randomly
selected samples of normal white matter and/or brain adja-
cent to tumour zone were immunoreacted with serially
diluted antibody preparations. Immunoreactivity in normal
white matter for EGF-R became undetectable at a dilution of
1 in 400 and cut-off dilutions for c-myc, HaIN-ras and c-fos
were 1 in 500, 1 in 700 and 1 in 1,800 respectively. The same
antibody preparations were used throughout the study.
Statistical analysis ofdata
Statistically significant differences in the occurrence of
overexpression of each oncogene and co-overexpression of
two, three or four oncogenes between each of the three
tumour groups were determined by 95% confidence intervals
(95% CI), Fisher's exact test and test for trend in proportion
(Armitage & Berry, 1987).
Results
Pattern ofoverexpression ofoncogenes in astrocytic tumours
The data are summarised in Table I which shows the number
of astrocytomas of each grade, as well as the percentage of
astrocytomas of each grade showing overexpression of each
of the four oncogenes.
No pattern of c-erbB-1 overexpression was observed across
the different grades of astrocytoma. Elevated expression of
c-erbB-1 was observed in 19/20 (95%) and 18/21 (86%) of
low grade tumours and glioblastoma multiforme respectively,
but in only 10/21 (48%) of anaplastic astrocytomas. There
was a significant difference in the percent of tumours with
overexpression of this oncogene between low grade tumours
and anaplastic astrocytomas (95% CI; 23,71) and between
anaplastic astrocytomas and glioblastoma multiforme (95%
CI; 11,65). However, because of the occurrence of overexp-
ression of this oncogene in the majority of all grades of
astrocytomas, it would appear that activation of c-erbB-1
alone is not an indicator of progression. Overexpression of
the c-fos oncogene occurs in approximately equal numbers of
low grade tumours (11/20; 55%), anaplastic astrocytomas
(10/21; 48%) and glioblastoma multiforme (11/21; 52%), and
no significant differences were observed between any of the
groups. This suggests that, similar to the c-erbB-1 oncogene,
overexpression of the c-fos oncogene alone is not an
indicator of progression.108 J.M. ORIAN et al.
Figure 1 Elevated expression of the c-erbB-1, c-myc, Ha/N-ras and c-fos gene products in astrocytomas. Sections were
immunoreacted with antibodies against EGF-R (diluted 1 in 400), c-myc (diluted 1 in 500), Ha/N-ras (diluted 1 in 700) and c-fos
(diluted 1 in 1,800), then incubated with a gold-labelled second antibody. Following incubation in physical development solution
sections were counterstained with Nuclear Fast Red B. a, glioblastoma multiforme immunoreacted with anti-EGF-R, x 1000; b,
glioblastoma multiforme immunoreacted with anti-c-myc, ). JQ00; (.c) anaplastic astrocytoma immunoreacted with anti-Ha/N-
ras, x 1000; d, anaplastic astrocytoma immunoreacted with anti-c-fos, x 1000; e, anaplastic astrocytoma shown in c, in the absence
of primary antibody, x 400; f, normal brain immunoreacted with anti-EGF-R (diluted 1 in 100) which had been absorbed with
EGF-R peptide, x 400. Identical results were obtained when normal brain was immunoreacted with antibodies absorbed with the
c-myc, Ha/N-ras and c-fos peptides. Positive immunoreactivity was detected- as the presence of silver gr-ains; Silver grains were
concentrated predominantly outside nuclei in sections immunoreacted with anti-EGF-R and anti-Ha/N-ras antibodies and
predominantly over nuclei in sections immunoreacted with anti-c-myc antibody. In the case of sections immunoreacted with
anti-c-fos antibody, silver grains appeared to be concentrated predominantly over nuclei, but significant cytoplasmic immunoreac-
tivity was also observed. This is in agreement with previous studies which have shown a similar pattern of subcellular localisation
of the fos product (Curran et al., 1984; Curran et al., 1985).
Ha/N-ras overexpression was not observed in any of the
low grade astrocytomas, but was present in 9/21 (43%) of
anaplastic astrocytomas and 15/21 (71%) glioblastoma mul-
tiforme. Because no low grade tumours were found to
overexpress Ha/N-ras, a confidence interval test to determine
the significance or otherwise of the difference between low
grade tumours and anaplastic astrocytomas could not be
performed. There was no significant difference in Ha/N-ras
overexpression between anaplastic astrocytomas and glio-
blastoma multiforme (-0.9,58). However, to determine
whether there was a statistically significant increase in the
percent of tumours with Ha/N-ras overexpression across theMULTIPLE ONCOGENE OVEREXPRESSION IN ASTROCYTOMAS 109
Table I Elevated expression of the c-erbB-1, c-myc, Ha/N-ras and c-fos genes in astrocytic tumours expressed as percentage (95% confidence
intervals) of total number of tumours
c-erbB-1 c-myc HaIN-ras c-fos
n % (95%, Cl) n % (95%, Cl) n % (95%, Cl) n % (95%, Cl)
Low grade n=20 19 95 (85, 105) 1 5 (-5.2, 15) 0 - - 11 55 (32.78)
Anaplastic n = 21 10 48 (25, 60) 7 33 (19, 55) 9 43 (20, 65) 10 48 (25, 70)
astrocytoma
Glioblastoma n = 21 18 86 (70, 102) 16 76 (57, 96) 15 71 (51, 92) 11 52 (30, 75)
multiforme
Tissue sections were immunoreacted asdescribed in Materialsandmethods. Results areexpressed asthenumberoftumoursineachgradeshowing
overexpression of the individual oncogenes and as a percentage of the total number of tumours in each grade. In a high proportion of cases
overexpression of more than one oncogene product was observed (see Table II).
three tumour grades, the test for trend in proportions was
performed and the result was found to be highly significant
(P<0.001). This suggests that the occurrence of Ha/N-ras
overexpression increases with the grade of the tumour.
Overexpression of c-myc occurred in 1/20 (5%) of low grade
tumours, 7/21 (33%) of anaplastic astrocytomas and 16/21
(76%) of glioblastoma multiforme. There was a significant
difference between the number of low grade tumours and
anaplastic astrocytomas (95% CI; 5,51) and the number of
anaplastic astrocytomas and glioblastoma multiforme (95%
CI; 15,71) overexpressing this oncogene. The test for trend in
proportions also showed that the increase in percent of
tumours overexpressing c-myc across the three tumour grades
was highly significant (P<0.001). This suggests that overexp-
ression of c-myc similar to that of Ha/N-ras, may be an
indicator of progression.
Oncogene co-expression in glial tumours
The pattern of co-overexpression of oncogenes in each grade
of tumour is shown in Table II. It appears that the number
of oncogenes co-overexpressed in the different grades of ast-
rocytoma increases with the grade of tumour. Low grade
tumours (12/20) co-overexpressed a maximum of two of the
oncogenes under investigation, anaplastic astrocytomas a
maximum of three of these oncogenes (4/21) and co-
overexpression of all four oncogenes was observed in a
number of glioblastoma multiforme (4/21).
Co-overexpression of two oncogenes No significant difference
was observed in co-overexpression of only two oncogenes in
the three tumour groups (P<0.1). The combination of c-
erbB-l/c-fos (11/20) was frequently observed in low grade
astrocytomas (11 cases). It was not observed in anaplastic
astrocytomas and was found in a single case of glioblastoma
multiforme. This suggests that the most likely grade of a
tumour co-overexpressing only this combination of
oncogenes is low grade.
Co-overexpression of three oncogenes To determine statis-
tically significant differences in co-overexpression -of three
oncogenes between low grade tumours, anaplastic ast-
rocytomas and glioblastoma multiforme the total number of
cases co-overexpressing three oncogenes in each group was
used (i.e. zero cases of low grade tumours, four cases of
anaplastic astrocytomas and 11 cases of glioblastoma mul-
tiforme; see Table II). Using chi-square analysis, a statis-
tically significant difference was observed between anaplastic
astrocytomas and glioblastoma multiforme (P<0.001). No
preferred combination of oncogenes was observed. However,
the combination of c-erbB-l1/c-myc/Ha/N-ras was most fre-
quently observed in glioblastoma multiforme, while the com-
bination c-erbB-1/Ha/N-ras/c-fos was most frequently
observed in anaplastic astrocytomas.
Co-overexpression offour oncogenes No cases of low grade
tumours or anaplastic astrocytomas were found to co-
overexpress four oncogenes. However four out of 21 glioblas-
toma multiforme were found to overexpress the four
oncogenes under investigation. Using a Fisher's exact test a
significant difference (P<0.03) was observed in the co-
TableII Co-overexpression ofthec-erbB-1,c-myc,Ha/N-rasandc-fos
gene products in astrocytic tumours
Anaplastic Glioblastoma
Lowgrade astrocytoma multiforme
Up tofour gene products
EGF-R/myc/ras/fos 0 0 4
Total 0 0 4
Up to three geneproducts
EGF-R/myc/ras 0 0 7
EGF-R/myc/fos 0 1 2
EGF-R/ras/fos 0 3 1
myc/ras/fos 0 0 1
Total 0 4 11
Up to two gene products
EGF-R/myc 1 6 0
EGF-R/ras 0 0 2
EGF-R/fos 11 0 1
myc/ras 0 0 0
myc/fos 0 0 2
ras/fos 0 4 0
Total 12 10 5
Co-overexpression of oncogene products was calculated. For each
grade oftumour, the number ofsamplesexpressing amaximum oftwo,
or three or four oncogene products is shown. Each ofthecombinations
shown is mutually exclusive. Each of the possible combinations were
sought and a zero incidence appears for those combinations that were
not observed.
overexpression of four oncogenes across the three tumour
grades.
Heterogeneity in staining pattern
A number of tissues showed heterogeneity in the staining
pattern in which the silver grains were not evenly distributed
over the whole of the tumour. This was most noticeable in
anaplastic astrocytomas immunoreacted with anti-EGF-R
and is illustrated in Figure 2. This observation suggests that
there may be some clones within the tumour at any one time
point in which genetic alterations are proceeding along
different pathways in different regions of the tumour.
Discussion
In contrast to previous studies which concentrated
predominantly on the activation of single oncogenes in gliob-
lastomas, this study has investigated the activation of a
number of oncogenes in low, intermediate and high grade
astrocytomas. The study was designed in this way to deter-
mine if a particular pattern of oncogene co-overexpression is
associated with histological grade. An immunohistological
technique was used to determine over-expression because the
study was performed on archival material, and because this
technique allows visualisation of expression in individual
tumour cells and of variation in expression in different
regions of the same tumour. None of these aspects is possible
with DNA and RNA blotting analyses and the latter techni-
ques also do not allow correction for the increased cellularity
of tumours.110 J.M. ORIAN et al.
Figure 2 Heterogeneous expression of the c-erbB-1 gene product in astrocytoma. Section from a single anaplastic astrocytoma was
immunoreacted with an antibody against the c-erbB-I gene product as described in the legend to Figure 1. Panels a and b show
differences in expression of c-erbB-1 in two different regions and panel c shows variation in c-erbB-1 expression between tumour
cells in the same region. x 1000.
We observed elevated expression of c-erbB-1 in all grades
of astrocytomas. The percentage of tumours showing
elevated expression of c-erbB-1 in low grade astrocytomas
was 95%. Elevated expression of this oncogene in low grade
astrocytomas has previously been demonstrated in only 9%
of cases by Reifenberger et al. (1989). However their study
included a number of low grade non-glial tumours in addi-
tion to low grade astrocytomas and the immunohis-
tochemical technique used (peroxidase-anti-peroxidase) was
different. Our data show that overexpression of c-erbB-l in
low grade astrocytomas is much higher than previously app-
reciated. We also observed elevated expression of c-erbB-l in
86% ofglioblastomas multiforme. This is comparable to data
obtained by Reifenberger et al. (1989) who showed elevated
expression in 79% of high grade astrocytomas by
immunohistochemical techniques and data obtained by
Malden et al. (1988) who showed elevated expression in 89%
of glioblastoma multiforme by Northern blot analysis of
total RNA. Malden et al. also demonstrated elevated levels
of EGF-R protein in a number of those glioblastomas by
Western blot analysis. Tuzi et al. (1991) found elevated exp-
ression of EGF-R in 29% of glial tumours but could not
detect gene rearrangements in any of these cases. Interest-
ingly cell lines derived from these tumours did not show
overexpression of EGF-R. It was suggested that EGF-R
amplification may confer a selective advantage in vivo, but
not in vitro.
The percentage of tumours overexpressing c-erbB-1 was
lower in anaplastic astrocytomas (48%) than in low grade
tumours (95%) and glioblastoma multiforme (86%) (Table
I). The reason for this observation is not clear, but may be
related to the occurrence of different types of mutations in
this oncogene in the different grades of tumours. It is well
documented that the c-erbB-l gene often undergoes extensive
amplification and rearrangement in glioblastoma multiforme
as a result of which the extracellular portion of the molecule
is deleted (Liberman et al., 1985; Malden et al., 1988; Wong
et al., 1987). The anti-EGF-R monoclonal antibody used is
directed against the extracellular portion of the molecule.
One interpretation of our data would therefore be that c-
erbB-1 overexpression occurs in all gliomas but re-
arrangement of the gene resulting in the truncation of the
EGF-R molecule is more common in anaplastic astrocytomas
than in glioblastoma multiforme.
Elevated expression of the c-myc oncogene has been
reported in isolated glial tumours (Englehard et al., 1989;
Trent et al., 1986), and there is a single report of elevated
expression of N-ras in five glioblastomas (Gerosa et al.,
1988). Our data show that elevated expression of both c-myc
and Ha/N-ras is a common feature of anaplastic ast-
rocytomas and glioblastoma multiforme. Elevated expression
of c-fos in astrocytomas has not been reported to our
knowledge. Our data show that overexpression of this
oncogene occurs in approximately 50% of all grades of
astrocytoma.
A study aimed at identifying markers of tumour progres-
sion would ideally require the analysis of serial samples from
the same set of patients. However ethical and practical con-
siderations make this approach impossible in the case of
astrocytic tumours.. It is therefore necessary to draw con-
clusions from a cross-sectional study. A statistically signi-
ficant difference in overexpression of c-erbB-1 was found
between low grade tumours, anaplastic astrocytomas and
glioblastoma multiforme. However, we are not able to con-
clude that overexpression of c-erbB-1 is associated with
progression since 95% of low grade tumours showed over-
expression of this oncogene. The low grade astrocytomas in
this study were of the juvenile pilocytic type in which pro-
gression occurs very rarely (Wallner et al., 1988). It is to be
noted that in a study of EGF-R activity in intracranial
tumours, Hawkings et al. (1991) also concluded that EGF-R
was of little prognostic significance. Overexpression of c-fos
was found in approximately equal numbers of low grade
tumours, anaplastic astrocytomas and glioblastoma multi-
forme and similarly does not appear to be significantly
associated with any one grade of astrocytoma or with pro-
gression. An interesting finding was that 11 of 20 low grade
tumours overexpressed the combination of c-erbBl and c-fos.
This combination was not observed in anaplastic astro-
cytomas and was found in only one glioblastoma multiforme.
This suggests that tumours found to be expressing the com-
bination c-erbB-1/c-fos are more likely to be low grade and
that they are unlikely to progress. On the other hand the
proportion of samples overexpressing c-myc or Ha/N-ras
increased with tumour grade. A test for trend in proportions,
which is the more accurate statistical method to determine
the significance of the increase observed across the three
tumour grades showed this increase to be highly significant in
each case, which strongly suggests that these two oncogenes
are good candidates as markers of progression. Expression of
the c-myc oncogene, has been shown to be related to the cell
cycle. During the GO phase there is a low level of c-myc
expression. When cells are stimulated to divide, endogenous
c-myc levels increase as cells progress from the GO to the G1MULTIPLE ONCOGENE OVEREXPRESSION IN ASTROCYTOMAS 111
and S phases of the cell cycle (Cole, 1986). Enhanced expres-
sion of c-myc in astrocytic tumours may simply be an indica-
tion that a higher proportion of cells are in a proliferative
phase compared with normal brain, but detection of this at
any one time point may be an important indication of the
likelihood of tumour progression.
Despite the relatively small number of tumours examined,
our data strongly suggest that there is an increase in the
number of oncogenes overexpressed concurrent with an in-
crease in the severity of the tumour. Glioblastoma multi-
forme overexpressed more oncogenes than anaplastic and low
grade astroctyomas. The current hypothesis regarding the
molecular basis of tumour progression implies that onco-
proteins act at all levels of signal transduction and that their
deregulated expression drives cell proliferation (Hunter,
1991). Recent evidence strongly suggests that sequential in-
activation of oncogenes occurs hand-in-hand with loss of
putative tumour suppressor genes (Marshall, 1991) and that
both phenomena contribute to tumour initiation and progres-
sion. It is possible that overexpression of at least some of the
four oncogenes in our study is a consequence of chromo-
somal aberrations and that their gene products may not work
in collaboration to generate the tumour phenotype. On the
other hand our data is in agreement with observations that
mutational events do not have to occur in a particular
sequence to promote tumour progression (Hunter, 1991) and
that it is the total accumulation of mutations which is the
crucial factor in determining progression to malignancy.
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